Zucara Therapeutics, a diabetes life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, recently announced that it has dosed the first patient in its Phase 2a trial of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes.
Zucara Therapeutics is an OBIO® member and presented at the OBIO® Investment Summit.